ReviewCardiovascular drugs and therapy2026
Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Variants in NOS2 and CCL2 Modulate Risk of Post-COVID-19 Hyperglycemia via Immune-Metabolic Interactions.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) are among the most prevalent and lethal chronic diseases worldwide. These conditions frequently coexist, forming a vicious “diabetes–coronary artery disease” cycle. Epidemiological evidence indicates that patients with T2DM have a two- to fourfold higher risk of developing CAD than healthy individuals. Moreover, among patients with CAD, the presence of T2DM is associated with significantly increased rates of recurrent myocardial infarction, heart failure, and mortality, posing substantial challenges to clinical management. Traditional studies have largely focused on the detrimental effects of isolated risk factors, such as hyperglycemia and dyslipidemia, on the cardiovascular system. However, recent advances in molecular biology have demonstrated that CAD and T2DM share a complex network of cellular and molecular pathological mechanisms. Moving beyond the conventional framework of individual risk factors, this article systematically summarizes the common pathophysiological basis of these two disorders from key perspectives including insulin resistance, chronic low-grade inflammation, and oxidative stress, with particular emphasis on the interactions among these mechanisms. In addition, in light of current therapeutic advances, it discusses treatment strategies targeting shared molecular pathways to facilitate the development of novel multitargeted interventions and to provide a theoretical basis for improving the prognosis of patients with this comorbidity.
Indexed as
Identifiers
42033571What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.